Obesity and the rising incidence of oesophageal and gastric adenocarcinoma: What is the link?

Gut

Volumn 56, Issue 11, 2007, Pages 1493-1494

  Corley, Douglas A ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; BODY MASS; CANCER RISK; DISEASE ASSOCIATION; DISEASE COURSE; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GEOGRAPHY; HUMAN; INCIDENCE; NOTE; OBESITY; PREVALENCE; PRIORITY JOURNAL; STOMACH CARCINOMA;

ADENOCARCINOMA; AGE FACTORS; BODY MASS INDEX; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; MALE; OBESITY; SEX FACTORS; STOMACH NEOPLASMS;

EID: 35648954569     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.124255     Document Type: Note

References (30)

1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.
2. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
3. Corley DA, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst 2004;96:1383-7.
4. Corley D, Buffler P. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:1415-25.
5. Kubo A, Corley DA. Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 2002;95:2096-102.
6. Kubo A, Corley DA. Marked multi-ethnic variation of esophageal and gastric cardia carcinomas within the United States. Am J Gastroenterol 2004;99:582-8.
7. Merry AHH, Schouten U, Goldbohm RA, et al. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut 2007;56:1503-11.
8. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;143:199-211.
9. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:872-8.
10. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004;127:310-30.
11. Corley DA, Kubo A. Body mass index and gastroesophageal reflux disease: a systematic review and meta-analysis. Am J Gastroenterol 2006;101:2619-28.
12. Corley DA, Kubo A, Zhao W. Abdominal obesity, ethnicity, and gastroesophageal reflux disease. Gut 2006;56:756-62.
13. Westhoff B, Brotze S, Weston A, et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005;61:226-31.
14. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007;133:34-41.
15. Moe GL, Kristal AR, Levine DS, et al. Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer 2000;36:7-13.
16. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002;11:745-52.
17. El-Serag HB, Petersen NJ, Carter J, et al. Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 2004;126:1692-9.
18. El-Serag HB, Kvapil P, Hacken-Bitar J, et al. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005;100:2151-6.
19. Samanic C, Gridley G, Chow WH, et al. Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 2004;15:35-43.
20. Schapira DV, Kumar NB, Lyman GH, et al. Abdominal obesity and breast cancer risk. Ann Intern Med 1990;112:182-6.
21. El-Serag HB, Tran T, Richardson P, et al. Anthropometric correlates of intragastric pressure. Scand J Gastroenterol 2006;41:887-91.
22. Stoll BA. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 2002;26:747-53.
23. Giacosa A, Franceschi S, La Vecchia C, et al. Energy intake, overweight, physical exercise and colorectal cancer risk. Eur J Cancer Prev, 1999;8(Suppl 1), S53-60.
24. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106.
25. Schoen RE, Schragin J, Weissfeld JL, et al. Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. Cancer Epidemiol Biomarkers Prev 2002;11:581-6.
26. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut, 2005;54(Suppl 1), i1-5.
27. Bolukbas FF, Kilic H, Bofukbas C, et al. Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer 2004;4:29.
28. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340: 1158-66.
29. Lord GM. Leptin as a proinflammatory cytokine. Contrib Nephrol 2006;151:151-64.
30. de Martel C, Haggerty TD, Corley DA, et al. Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. Am J Gastroenterol 2007;102:1166-72.